Data Sheet (Cat.No.T16477)

TargetMol

PF-03715455

Chemical Properties



CAS No. : 1056164-52-3

Formula: C35H34ClN7O3S2

Molecular Weight: 700.27

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-03715455 has the potential for the treatment of COPD.
Targets(IC50)	p38 MAPK
In vitro	PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6, and a potent inhibitor of CYP2C9 and CYP3A4[2].
In vivo	PF-03715455 treatment displays that the Vss is 0.19 L/kg and T1/2 is 1 hour [2].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.428 mL	7.1401 mL	14.2802 mL
5 mM	0.2856 mL	1.428 mL	2.856 mL
10 mM	0.1428 mL	0.714 mL	1.428 mL
50 mM	0.0286 mL	0.1428 mL	0.2856 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.

Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54(22):7797-814.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481